Broad-spectrum antibiotics associated gut microbiome disturbance impairs T cell immunity and promotes lung cancer metastasis: a retrospective study

Table 12 Effect of treatment line or therapeutic regimen on T cell immunity in patients with stage III NSCLC

Treatment	Item	Non-ATB (n = 78)	n	ATB (n = 37)	n	P value
First line	CD4+	42.83 ± 9.36	78	37.08 ± 10.28	37	0.004
First line	CD8+	23.15 ± 7.42	78	19.10 ± 5.14	37	0.003
Subsequent lines	CD4+	40.62 ± 14.70	18	34.49 ± 9.19	10	0.035
Subsequent lines	CD8+	22.76 ± 9.65	18	23.29 ± 6.17	10	0.181
Chemotherapy	CD4+	44.10 ± 9.81	55	36.95 ± 11.07	34	0.002
Chemotherapy	CD8+	22.68 ± 7.55	55	19.46 ± 5.36	34	0.033
Other treatment	CD4+	40.16 ± 11.11	41	35.45 ± 8.96	13	0.171
Other treatment	CD8+	23.60 ± 8.27	41	21.38 ± 6.13	13	0.376

ISSN: 1471-2407